Original Research
Accepted on 24 Jul 2025
Cost-effectiveness analysis of toripalimab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China
in Drugs Outcomes Research and Policies